This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Illumina, Grail should win appeals against EU Commission’s jurisdiction over their merger, legal opinion says

( March 21, 2024, 09:09 GMT | Official Statement) -- MLex Summary: US life-sciences company Illumina and cancer-testing startup Grail should win their legal challenges to the European Commission's jurisdiction to review their merger, according to a non-binding legal opinion for the EU's top court. Advocate General Nicholas Emiliou is of the view that EU national competition authorities may not ask the commission to examine a concentration that does not have an EU dimension where they have no competence to review such a concentration under national law.The statement and the AG Opinion are attached. Case references are C-611/22 & C-625/22. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login